Analyses of the stigma associated with mental patients have been exhaustively developed. Some of these analyses refer to the general population in different countries, some other compare conclusions from these countries, and some others discuss the attitutes of either current or future (psychiatric and non-psychiatric) health professionals with respect to mental illness. Most of these analyses are based on well-known questionnaires (usually on their country-adapted versions), each of them corresponding to a multi-item scale evaluated using either a 5-, 6-or 7-point Likert scale and focussing on different attitudinal factors or constructs. This paper introduces a quite preliminary study in this setting, aiming to examine the influence of the medical specialty on the perception about mental patients and involving a more expressive and flexible scale to rate attitudes: the fuzzy rating scale (allowing a free fuzzy set-valued response assessment to items).
IntroductionCompliance is essential to achieve the best results in serious mental illness like schizophrenia.ObjectivesIt was expected that the use of second-generation oral antipsychotics with less extrapyramidal side effect profile would improve the compliance, but the results do not support these expectations except in the case of risperidone long-acting injection.AimsThe aim of this study is to assess the degree of compliance in outpatients who were started treatment with RLAI while they were hospitalized for an acute psychotic episode in psychiatric unit.MethodsA retrospective study was conducted by reviewing medical records of hospitalized patients for psychotic episodes over the past 5 years in three hospitals in Mallorca (Balearic Islands, Spain) -Hospital de Manacor, Hospital son Llatzer and Hospital de Inca). Due to computerization of medical records, we knew the degree of compliance with treatment and outcome in outpatient clinics. We designed a case report data (CRD) to assess specific variables in our study that was completed for each patient.ResultsThe mean duration of treatment in patients who continue with RLAI was 38.8 months. Overall. 69.5% continued with the treatment after 5 years. The patients who continued treatment were rehospitalazed 20% less than the ones who discontinued.ConclusionsThe compliance with RLAI in outpatients was high even in patients with substances abuse. The patients who remain on treatment from hospital discharge have less readmissions. The most common dosis of RLAI is 50 mg. Lack of insight was the most frequent cause of discontinuation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.